Evidence map›Paper›PMID 29572501›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information.

Christian Koelsche, Wolfgang Hartmann, Daniel Schrimpf, Damian Stichel, Susanne Jabar, Andreas Ranft, David E Reuss, Felix Sahm, David T W Jones, Melanie Bewerunge-Hudler and 16 more

Open access · greenAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The DNA methylation landscape of musculoskeletal sarcomas.Exploration of targeted anti-tumor therapy · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Unlocking epigenetics for precision treatment of Ewing's sarcoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord.Neuropathology : official journal of the Japanese Society of Neuropathology · 2022
    Article
  17. Article
  18. Small round cell sarcomas.Nature reviews. Disease primers · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 12 institutions in 5 countries.

Christian KoelscheClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-8763-8864
Wolfgang HartmannGerhard-Domagk-Institute of Pathology, Muenster University Hospital, Muenster, Germany.
Daniel SchrimpfClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Damian StichelClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Susanne JabarPediatrics III Pediatric Hematology, Oncology, Immunology, Cardiology, Pulmonology, West German Cancer Centre, University Hospital Essen, Essen, Germany.
Andreas RanftPediatrics III Pediatric Hematology, Oncology, Immunology, Cardiology, Pulmonology, West German Cancer Centre, University Hospital Essen, Essen, Germany.
David E ReussClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Felix SahmClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
David T W JonesGerman Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
Melanie Bewerunge-HudlerGerman Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9038-7891
Marcel TrautmannGerhard-Domagk-Institute of Pathology, Muenster University Hospital, Muenster, Germany.ORCID http://orcid.org/0000-0002-5842-1196
Thomas KlingebielDepartment of Pediatric Hematology and Oncology, University Children's Hospital, Frankfurt/Main, Germany.
Christian VokuhlDepartment of Pediatric Pathology, University Hospital of Schleswig-Holstein, Kiel, Germany.
Manfred GesslerTheodor-Boveri-Institute/Biocenter, Developmental Biochemistry, Wuerzburg University, Wuerzburg, Germany.ORCID http://orcid.org/0000-0002-7915-6045
Eva WardelmannGerhard-Domagk-Institute of Pathology, Muenster University Hospital, Muenster, Germany.
Iver PetersenInstitute of Pathology, SRH Poliklinik Gera GmbH, Gera, Germany.
Daniel BaumhoerBone Tumour Reference Centre at the Institute of Pathology, University Hospital Basel and University of Basel, Basel, Switzerland.
Uta FluckeDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Cristina AntonescuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
Manel EstellerCancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Catalonia, Spain.
Stefan FröhlingGerman Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
Marcel KoolGerman Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
Stefan M PfisterGerman Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
Gunhild MechtersheimerDepartment of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Uta DirksenPediatrics III Pediatric Hematology, Oncology, Immunology, Cardiology, Pulmonology, West German Cancer Centre, University Hospital Essen, Essen, Germany. uta.dirksen@uk-essen.de.
Andreas von DeimlingClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. andreas.vondeimling@med.uni-heidelberg.de.
German Cancer Research Center · DEDeutschen Konsortium für Translationale Krebsforschung · DEEssen University Hospital · DEGoethe University Frankfurt · DEHeidelberg University · DEInstitució Catalana de Recerca i Estudis Avançats · ESMemorial Sloan Kettering Cancer Center · USRadboud University Nijmegen · NLSRH Wald-Klinikum Gera · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Basel · CHUniversity of Würzburg · DE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Undifferentiated solid tumors with small blue round cell histology and expression of CD99 mostly resemble Ewing sarcoma. However, they also may include other tumors such as mesenchymal chondrosarcoma, synovial sarcoma, or small cell osteosarcoma. Definitive classification usually requires detection of entity-specific mutations. While this approach identifies the majority of Ewing sarcomas, a subset of lesions remains unclassified and, therefore, has been termed "Ewing-like sarcomas" or small blue round cell tumors not otherwise specified. We developed an approach for further characterization of small blue round cell tumors not otherwise specified using an array-based DNA-methylation profiling approach. Data were analyzed by unsupervised clustering and t-distributed stochastic neighbor embedding analysis and compared with a reference methylation data set of 460 well-characterized prototypical sarcomas encompassing 18 subtypes. Verification was performed by additional FISH analyses, RNA sequencing from formalin-fixed paraffin-embedded material or immunohistochemical marker analyses. In a cohort of more than 1,000 tumors assumed to represent Ewing sarcomas, 30 failed to exhibit the typical EWS translocation. These tumors were subjected to methylation profiling and could be assigned to Ewing sarcoma in 14 (47%), to small blue round cell tumors with CIC alteration in 6 (20%), to small blue round cell tumors with BCOR alteration in 4 (13%), to synovial sarcoma and to malignant rhabdoid tumor in 2 cases each. One single case each was allotted to mesenchymal chondrosarcoma and adamantinoma. 12/14 tumors classified as Ewing sarcoma could be verified by demonstrating either a canonical EWS translocation evading initial testing, by identifying rare breakpoints or fusion partners. The methylation-based assignment of the remaining small blue round cell tumors not otherwise specified also could be verified by entity-specific molecular alterations in 13/16 cases. In conclusion, array-based DNA-methylation analysis of undifferentiated tumors with small blue round cell histology is a powerful tool for precisely classifying this diagnostically challenging tumor group.

Indexed as

AdolescentAdultChildChild, PreschoolDNA MethylationFemaleGene Expression ProfilingHumansInfantInfant, NewbornMaleMiddle AgedSarcoma, Small CellYoung Adult

Identifiers

PMID29572501
PMCPMC7484949
OpenAlexW2793833695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.